”Another non-NGS example which gives us great joy is the huge advantage patients with elevated CRP enjoy from Revascor. No genetic analysis required there, just a simple blood test.”
Yes the utility from the simple blood test and any heightened CRP will be magnified when used to make this medicine more “precise”. It should help physicians and patients alike by providing something measurable and tangible to point to in predicting how useful the treatment may be. Will surely help take-up of the product and market penetration.
”Another non-NGS example which gives us great joy is the huge...
-
- There are more pages in this discussion • 393 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |